ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO942

Modest Reductions in Kidney Function and Adverse Outcomes in Young Adults

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Hussain, Junayd, University of Ottawa School of Epidemiology and Public Health, Ottawa, Ontario, Canada
  • Canney, Mark, University of Ottawa School of Epidemiology and Public Health, Ottawa, Ontario, Canada
  • Elliott, Meghan J., University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
  • Hundemer, Gregory L., University of Ottawa School of Epidemiology and Public Health, Ottawa, Ontario, Canada
  • Tangri, Navdeep, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
  • Sood, Manish M., Institute of Clinical and Evaluative Sciences (ICES), University of Ottawa, Ottawa, Ontario, Canada
Background

Whether modest declines in estimated glomerular filtration rate (eGFR below age-expected values) in younger adults are associated with adverse outcomes is unknown. We aim to estimate the association of an early eGFR decline with adverse outcomes by age group (18-39, 40-49, 50-65 years).

Methods

We included 8.7 million adults (aged 18-65) with ≥1 eGFR value using linked healthcare datasets in Ontario from January 2008-March 2020. The association of eGFR categories from <60 to >120 mL/min/1.73m2 and adverse outcomes (death, cardiovascular outcomes, end-stage kidney disease) was examined using adjusted Cox models. Comparisons were relative to age normalized measured GFR categories (100-110 mL/min for 18-39, 90-100 mL/min for 40-49, 80-90 mL/min for 50-65).

Results

The mean age, eGFR and median follow up were 41 years, 104 mL/min and 9.2 years, respectively. 17.3%, 18.9%, and 17.7% had an eGFR below normal for ages 18-39, 40-49, and 50-65, respectively. The risk of an adverse event increased in a stepwise manner with eGFR values below the referent and occurred at higher eGFR values in those 18 to 39 [eGFR 70-80, age 18-39: incidence 4.37 events per 1000 person-years [p-y], HR 1.54(1.46-1.61); age 40-49: incidence 9.78 per 1000p-y, HR 1.18(1.15-1.21); age 50-65: incidence 24.0 per 1000p-y, HR 1.11(1.10-1.12)] (see Figure). Results persisted for each outcome individually, and after using repeated eGFR, using a common referent, and adjusting for multiple covariates.

Conclusion

Young adults (18-39) with an early eGFR decline were at a higher risk of adverse events and this occurred at higher eGFR levels relative to middle-aged and older adults.

Figure: Incidence rates (events per 1000 person-years) and adjusted hazard ratios (HRs, 95% CI) for any adverse outcome (first of all-cause mortality, cardiovascular outcomes, end-stage kidney disease) relative to age-specific eGFR reference ranges, by age-group.